levodopa-carbidopa intestinal gel

levodopa-carbidopa intestinal gel
Name	Levodopa-carbidopa intestinal gel
Specialty	Neurology
Type	Continuous intestinal infusion
Target	Parkinson's disease
Drug class	Dopamine precursor / Decarboxylase inhibitor
Synonyms	LCIG
Trade names	Duodopa
Legal status	EU: Rx-only, US: Rx-only
Routes of administration	Jejunal infusion

levodopa-carbidopa intestinal gel. It is a specialized gel formulation administered via a portable infusion pump directly into the small intestine for the treatment of advanced Parkinson's disease. This therapy is designed to provide continuous dopaminergic stimulation, mitigating the motor fluctuations and dyskinesia associated with long-term oral levodopa therapy. It is indicated for patients with severe motor complications that are no longer adequately controlled by optimized oral pharmacotherapy.

Medical uses

Levodopa-carbidopa intestinal gel is specifically approved for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson's disease medication have not given satisfactory results. Its use is typically reserved for patients who have exhausted other advanced therapies, such as deep brain stimulation or apomorphine infusion. Treatment decisions are made by a multidisciplinary team often involving a movement disorder specialist at a specialized Parkinson's Foundation Center of Excellence. Patient selection criteria include a confirmed response to levodopa but with debilitating "off" periods and unpredictable motor symptom control.

Administration and dosing

Administration requires a minor surgical procedure for the placement of a percutaneous endoscopic gastrostomy tube with a jejunal extension. The gel is contained in cassettes that are attached to a portable, battery-operated infusion pump, which delivers the medication continuously over 16 hours. A typical dosing regimen includes a morning bolus dose followed by a continuous maintenance infusion, with additional bolus doses available for managing sudden "off" episodes. The system is managed by the patient or caregiver, with training provided by healthcare professionals from institutions like the Cleveland Clinic or Mayo Clinic.

Mechanism of action

The gel contains a combination of levodopa, the metabolic precursor to dopamine, and carbidopa, a peripheral aromatic L-amino acid decarboxylase inhibitor. By infusing directly into the jejunum, the formulation bypasses the stomach, where erratic gastric emptying can cause variable absorption of oral tablets. This provides more stable plasma concentrations of levodopa, leading to continuous dopaminergic stimulation in the brain. This steady delivery mimics physiological dopamine release more closely than pulsatile oral dosing, which is thought to underlie the reduction in motor complications.

Clinical efficacy and evidence

Efficacy is supported by several pivotal clinical trials, including the double-blind, double-dummy phase III clinical trial published in the Lancet Neurology. Studies consistently demonstrate significant reductions in daily "off" time and increases in "on" time without troublesome dyskinesia compared to optimized oral levodopa therapy. Long-term open-label studies, such as those reported in the Journal of Parkinson's Disease, show sustained benefits over several years. The therapy's effect on quality of life has been measured using standardized tools like the Parkinson's Disease Questionnaire.

Adverse effects and safety

The most common adverse events are related to the percutaneous endoscopic gastrostomy procedure and the device, including postoperative complications, peritonitis, pneumoperitoneum, and tube dislodgement. Medication-related side effects include neuropsychiatric symptoms, impulse control disorder, and peripheral neuropathy. There is a risk of polyneuropathy, potentially linked to vitamin B6 metabolism, necessitating monitoring. Safety data is continually reviewed by regulatory bodies like the Food and Drug Administration and the European Medicines Agency.

History and development

The development of intestinal gel infusion was pioneered in the late 1980s and 1990s by researchers in Sweden, including teams at Lund University. The concept aimed to address the pharmacokinetic shortcomings of oral levodopa by providing continuous duodenal delivery. The gel formulation, later trademarked as Duodopa, was developed by the Swedish company Neuroscience and later acquired by AbbVie Inc.. It received European Commission approval in 2004 and was subsequently approved by the Food and Drug Administration in 2015 following the results of the pivotal phase III trial.

Category:Parkinson's disease Category:Dopaminergic agents Category:Infusion therapy